Creative journey begins with a first-ever 3D pen project inspired by a unique game character, transforming a simple 2D cat design into a full 3D model with expressive interchangeable faces. The ...

An investigational oral drug that targets RAS, the dominant oncogenic driver in pancreatic cancer, nearly doubled overall survival compared with common second-line chemotherapy regimens in patients ...

At the moment, RevMed remains keenly focused on its mission to bring daraxonrasib to the masses and continue developing new medicines that target RAS. (Darren Incorvaia) This year’s meeting of the ...

At 3DExperience 2026, SolidWorks introduced AI companions Aura, Leo and Marie, set for release in summer. Live demonstrations showcased AI converting 2D sketches into 3D models within seconds, ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Photo: Christophe Gateau/dpa (Photo by Christophe Gateau/picture alliance via Getty Images) ...

LONDON, May 13 (Reuters) - Libya aims to restart its 220,000 barrel-per-day Ras Lanuf oil refinery within six to 12 months ‌to supply the domestic market, National Oil Corporation (NOC) chairman ...

To say there was a crowded field in the race for Newark mayor was putting it mildly. But in the end, it didn't matter. The Associated Press projects incumbent Ras Baraka, a progressive Democrat, will ...

They called it a “geriatric ghetto” and “God’s waiting room.” The sidewalks were cracked, the buildings were run-down and the population of Miami Beach’s South Beach neighborhood in the early 1980s ...

Krutrim, India’s first GenAI unicorn, is shifting from AI model development to cloud services after months of relative quiet on product updates — a move that reflects the tougher economics of building ...

State Appointed Superintendent Mike Miles answers questions about Future 2 Schools at a Virtual Question and Answer event held by the district. Houston ISD has earmarked seven more elementary and ...

Kestrel today announced that the first patient has been dosed in its phase 1 trial of KST-6051, an oral small molecule meant to inhibit multiple different kinds of KRAS mutations. (iStock / Getty ...